-
Summit Therapeutics Inc. (NASDAQ:SMMT) Q1 2025 Earnings Call Transcript
02 May 2025 13:09 GMT
… Summit Therapeutics Q1 2025 Earnings Conference Call. I would … issued this afternoon our earnings release for the first … major pharmaceutical companies, including Bayer Healthcare and Bristol-Myers. With … for attending today’s earnings call. We are unfortunately …
-
U.S. FDA Approves NUBEQA® (darolutamide) to Treat Patients with Metastatic Castration-Sensitive Prostate Cancer
03 Jun 2025 23:08 GMT
… Group aims to increase its earning power and create value through … ® (darolutamide) [Prescribing Information]. Whippany, NJ: Bayer HealthCare Pharmaceuticals, Inc.; June 2025.
Bray …
-
CORRECTING and REPLACING New XOFIGO® (radium-223 dichloride) Data in Metastatic Castration-Resistant Prostate Cancer from Phase III PEACE III Trial Published in Annals of Oncology
30 May 2025 19:00 GMT
… Group aims to increase its earning power and create value through … ) Injection [Prescribing Information]. Whippany, NJ: Bayer HealthCare Pharmaceuticals, December 2019.
Gillessen S …
-
ASCO 2025: XOFIGO® (radium-223 dichloride) Combination Data Showcases Clinical Benefits in Metastatic Castration-Resistant Prostate Cancer with Bone Metastases
28 May 2025 12:29 GMT
… Group aims to increase its earning power and create value through … ) Injection [Prescribing Information]. Whippany, NJ: Bayer HealthCare Pharmaceuticals, December 2019.
Choudhury A …
-
ASCO 2025: Phase III ARANOTE Post-hoc Analyses Presented on Health-Related Quality of Life and Pain Outcomes in Patients with Metastatic Castration-Sensitive Prostate Cancer Receiving NUBEQA® (darolutamide) plus ADT
27 May 2025 12:17 GMT
… Group aims to increase its earning power and create value through … ® (darolutamide) [Prescribing Information]. Whippany, NJ: Bayer HealthCare Pharmaceuticals, Inc.; October 2023.
Bray …
-
Bayer Highlights New Data from Oncology and Women’s Health Portfolios at 2025 ASCO Annual Meeting
21 May 2025 12:08 GMT
… aims to increase its earning power and create value … ) [Prescribing Information]. Whippany, NJ: Bayer HealthCare Pharmaceuticals, Inc.; October 2023.
XOFIGO … [Prescribing Information]. Whippany, NJ: Bayer HealthCare Pharmaceuticals, Inc.; October 2024.
Hyuna …
-
Vaxcyte Reports First Quarter 2025 Financial Results and Provides Business Update
07 May 2025 20:01 GMT
-- Company Reported Positive Topline Safety, Tolerability and Immunogenicity Data from Phase 2 Dose-Finding Study of VAX-24 in Healthy Infants; Balance of Data Expected by End of 2025 -- -- Initiated Second and Final Stage of VAX-31 Infant Phase 2 Dose- …
-
Medical Imaging Reagents Market Size and Forecast to 2021-2027 Analysis with Key Players || Bracco Imaging SpA, Bayer Healthcare AG
20 Aug 2021 05:45 GMT
… data such as economic scenarios, earnings, limits, current and future trends … globe includes Bracco Imaging SpA, Bayer Healthcare AG, Cardinal Health, Inc, Danaher …
-
Summit Therapeutics Reports Financial Results and Operational Progress for the First Quarter Ended March 31, 2025
01 May 2025 20:43 GMT
… the global oncology franchise at Bayer Healthcare and Senior Vice President and … press release.
First Quarter 2025 Earnings Call
Summit will host an … earnings call this afternoon, Thursday, May …
-
AUA 2025: New Data from Post-Hoc Analyses Shared on Ultra-Low Prostate-Specific Antigen (PSA) Response in Patients with Metastatic Hormone-Sensitive Prostate Cancer Receiving NUBEQA® (darolutamide) plus Androgen Deprivation Therapy (ADT)
29 Apr 2025 12:28 GMT
… Group aims to increase its earning power and create value through … ® (darolutamide) [Prescribing Information]. Whippany, NJ: Bayer HealthCare Pharmaceuticals, Inc.; October 2023.
Bray …
About
© 1995-2025